EXAS250117P120000
- 77.43
- 0.000.00%
Exact Sciences Newsroom
Exact Sciences Initiated at Overweight by Barclays
Exact Sciences Analyst Ratings
Barclays Initiates Exact Sciences(EXAS.US) With Buy Rating, Announces Target Price $70
Craig-Hallum Maintains Exact Sciences(EXAS.US) With Buy Rating
Exact Sciences (EXAS) Receives a Buy From Craig-Hallum
Exact Sciences: Strong Screening Revenue Growth and Strategic Initiatives Justify Buy Rating
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $65 to $86
Exact Sciences Price Target Maintained With a $65.00/Share by Benchmark
Exact Sciences Analyst Ratings
Craig-Hallum Sticks to Their Buy Rating for Exact Sciences (EXAS)
Analysts Conflicted on These Healthcare Names: Tilray (TLRY) and Exact Sciences (EXAS)
Exact Sciences (EXAS) Gets a Buy From TD Cowen
BofA Securities Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $72
Exact Sciences' Strong Q4 Performance and Growth Prospects Justify Buy Rating
Citi Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $75
Bernstein Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $70
Bernstein Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $70
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Inspire Medical Systems (INSP)
Evercore Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $70
Analysts Are Bullish on These Healthcare Stocks: Exact Sciences (EXAS), Neurocrine (NBIX)